Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, PR China.
Department of General Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, PR China.
FASEB J. 2024 Jul 31;38(14):e23829. doi: 10.1096/fj.202400458R.
G protein-coupled receptors (GPCRs) are essential contributors to tumor growth and metastasis due to their roles in immune cell regulation. Therefore, GPCRs are potential targets for cancer immunotherapy. Here, we discuss the current understanding of the roles of GPCRs and their signaling pathways in tumor progression from an immunocellular perspective. Additionally, we focus on the roles of GPCRs in regulating immune checkpoint proteins involved in immune evasion. Finally, we review the progress of clinical trials of GPCR-targeted drugs for cancer treatment, which may be combined with immunotherapy to improve treatment efficacy. This expanded understanding of the role of GPCRs may shed light on the mechanisms underlying tumor progression and provide a novel perspective on cancer immunotherapy.
G 蛋白偶联受体（GPCRs）在免疫细胞调节中发挥作用，是肿瘤生长和转移的重要贡献者。因此，GPCR 是癌症免疫治疗的潜在靶点。在这里，我们从免疫细胞的角度讨论了 GPCR 及其信号通路在肿瘤进展中的作用的最新认识。此外，我们还重点讨论了 GPCR 在调节参与免疫逃逸的免疫检查点蛋白中的作用。最后，我们回顾了 GPCR 靶向药物治疗癌症的临床试验进展，这些药物可能与免疫疗法联合使用，以提高治疗效果。对 GPCR 作用的这种扩展理解可能揭示肿瘤进展的机制，并为癌症免疫治疗提供新的视角。
